R. Pollock
Cancer Cell · 2010–2013
A researcher in the Science corpus: 6 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from R. Pollock's perspective
Ordered by how strongly the researchers R. Pollock trusts endorse each paper. Same corpus, a different order for every researcher.
- hDOT1L links histone methylation to leukemogenesis. (Cell)
- SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. (Molecules and Cells)
- MLL translocations, histone modifications and leukaemia stem-cell development (Nature Reviews. Cancer)
- High-resolution profiling of histone methylations in the human genome. (Cell)
- Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation (Cell Stem Cell)
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia (Nature Genetics)
- Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
- ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. (Molecules and Cells)
- Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. (Current Biology)
- EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. (Molecules and Cells)
Their papers
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor (2011) — 928 citations
- MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L (2011) — 883 citations
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. (2012) — 770 citations
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas (2010) — 682 citations
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. (2013) — 684 citations
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 (2013) — 742 citations